文献速递免疫规划

重组痘苗载体疫苗(天坛)加强新型HBV亚单位疫苗在恒河猴中诱导更强更持久免疫

Recombinant vaccinia vector-based vaccine (Tiantan) boosting a novel HBV subunit vaccine induced more robust and lasting immunity in rhesus macaques.
PubMed 文献 · Vaccine · 2017-05-06

本研究在恒河猴中比较多种新型乙肝病毒(HBV)疫苗的初免-加强策略,包括HBV颗粒亚单位疫苗(HBSS1)及含S(1-223aa)和PreS1(21-47aa)的重组痘苗(RVJSS1)或腺病毒(rAdSS1)载体疫苗。纵向随访至接种后79周,发现HBSS1/RVJSS1异源初免-加强诱导体液免疫与HBSS1/HBSS1同源接种相似,但细胞免疫更强更持久;HBSS1/RVJSS1/RVJSS1诱导的细胞免疫比HBSS1/HBSS1/rAdSS1更强更持久。

要点

  • HBSS1/RVJSS1异源初免-加强诱导体液免疫与HBSS1/HBSS1同源接种相似。
  • HBSS1/RVJSS1异源初免-加强诱导的细胞免疫比HBSS1/HBSS1同源接种更强更持久。
  • HBSS1/RVJSS1/RVJSS1诱导的细胞免疫比HBSS1/HBSS1/rAdSS1更强更持久。

核心结论

  • HBSS1/RVJSS1/RVJSS1是保护人类免受HBV感染最有希望的候选方案,尤其适用于治疗性应用。

研究设计与样本

  • 在恒河猴中开展纵向研究,比较多种新型HBV疫苗的初免-加强策略,随访至接种后79周。
  • 测试疫苗包括HBV颗粒亚单位疫苗(HBSS1)及含S(1-223aa)和PreS1(21-47aa)的重组痘苗(RVJSS1)或腺病毒(rAdSS1)载体疫苗。

主要发现

  • HBSS1/RVJSS1异源初免-加强诱导体液免疫与HBSS1/HBSS1同源接种相似,但细胞免疫比HBSS1/HBSS1更强更持久。
  • HBSS1/RVJSS1/RVJSS1诱导的细胞免疫比HBSS1/HBSS1/rAdSS1更强更持久。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study explored several prime-boost strategies in rhesus macaques using various novel hepatitis B virus (HBV) vaccines that showed promise as prophylactic and therapeutic approaches in our previous study using in a mouse model. The tested vaccines included an HBV particle subunit (HBSS1) vaccine and the recombinant vaccinia (RVJSS1) or adenoviral (rAdSS1) vector-based vaccines containing S (1-223aa) and PreS1 (21-47aa). The strength and maintenance of humoral activity (IgG and neutralizing antibodies) and cellular immunity (interferon-γ production assessed by IFN-γ enzyme-linked immunosorbent spot (ELISpot) assay) were investigated in a longitudinal study following various vaccination protocols until 79weeks post-vaccination. We found that HBSS1/RVJSS1 heterologous prime-boost elicits similar strong humoral immunity but more robust and lasting cellular immunity (CMI) than HBSS1/HBSS1 homologous vaccination in rhesus macaques. Furthermore, HBSS1/RVJSS1/RVJSS1 induced more robust and lasting CMI in macaques than did HBSS1/HBSS1/rAdSS1 vaccination. Therefore, HBSS1/RVJSS1/RVJSS1 is most promising candidates for protecting humans against HBV infection, especially for therapeutic application.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Deng Y, Chuai X, Chen P, et al. Recombinant vaccinia vector-based vaccine (Tiantan) boosting a novel HBV subunit vaccine induced more robust and lasting immunity in rhesus macaques. Vaccine. 2017. PMID: 28487055. doi:10.1016/j.vaccine.2017.04.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。